Trobix Bio is an Israeli biotech company pioneering the field of human microbiome via its TBX™ technology platform, utilizing CRISPR, phage and synthetic biology to re-program specific activities in targeted microbiome bacteria and develop orally administered precision oncology therapeutics.
Targeting cumulative markets of over $4 billion, Trobix’s preclinical products, TBX201 and TBX301, are being developed to reduce severe diarrhea and colitis in patients receiving irinotecan or checkpoint inhibitors, respectively. Its products may allow physicians to complete more oncology treatments and improve cancer patients’ quality of life.
Trobix Bio is a spin-off company of Ramot, the technology-transfer company of Tel Aviv University.
Cumulative Funding Raised Over Time ($)
Employees Over Time
Trobix Bio Climate Tech relevance
null
Latest News
No Data, yet.
Sorry, no content found under this section.
Mar 30, 2023
www.globenewswire.com
Trobix Bio Raises $3 Million from Chartered Group to Advance Precision Microbiome Oncology Therapeutics
#Investment
Jul 29, 2020
www.prnewswire.com
Trobix Bio completed Series A funding by a leading Japanese/Singapore fund
#Investment
Jul 6, 2020
ramot.org
Ramot- Technology Transfer Company of Tel Aviv University
undefined
Mar 6, 2019
globaluniversityventuring.com
Trobix Bio follows the funding trail - Global Venturing